Albireo Pharma Inc

NASDAQ:ALBO   3:59:57 PM EDT
28.49
-0.42 (-1.45%)
Products

Albireo Announces FDA Approval Of Bylvay™ (Odevixibat), The First Drug Treatment For Patients With Progressive Familial Intrahepatic Cholestasis (Pfic)

Published: 07/20/2021 20:32 GMT
Albireo Pharma Inc (ALBO) - Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (pfic).
Albireo Pharma Inc - Bylvay is Expected to Be Packaged and Shipped Within Coming Days.
Albireo Pharma Inc - Anticipates 2021 Operating Cash Burn Will Be Between $130-$135 Million.
Albireo Pharma Inc - Topline Data From Assert Trial is Expected in 2022 and Bold Trial Expected in 2024.